CD274 and prostate carcinoma: Other examples include the study of sera from prostate cancer patients where differentially expressed end points (e.g., programmed death-ligand 1 (PD-L1), CD274), survivin, and transforming growth factor beta were identified as deriving from T-EVs (107).